A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases
Abstract
:1. Introduction
2. Materials and Methods
2.1. Reagents
2.2. Chip and Multiple Biosensor Architecture
2.3. Antibody Immobilization
2.4. Measurement of Analytical Signals
2.5. Determination of CA125, HE4, CEA, IL-6 and Aromatase by the Array SPRi Technique Using Single Biosensors
3. Results
3.1. Calibration of the Multiple-Array Biosensor
3.2. Comparison of Results from the Multiple Biosensor with Those Obtained Using Single Biosensors
3.3. Examples of CA125, HE4, CEA, Il-6 and Aromatase Determination with the Multiple Biosensor in Real-Blood Serum Samples
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lukaszewski, Z.; Gorodkiewicz, E. Biosensors for the determination of protein biomarkers (edtitorial to SI). Biosensors 2023, 13, 112. [Google Scholar] [CrossRef] [PubMed]
- Szymanska, B.; Lukaszewski, Z.; Hermanowicz-Szamatowicz, K.; Gorodkiewicz, E. A biosensor for determination of the circulating biomarker CA125/MUC 16 by Surface Plasmon Resonance Imaging. Talanta 2020, 206, 120187. [Google Scholar] [CrossRef]
- Szymanska, B.; Lukaszewski, Z.; Zelazowska-Rutkowska, B.; Hermanowicz-Szamatowicz, K.; Gorodkiewicz, E. An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma. Sensors 2021, 21, 3567. [Google Scholar] [CrossRef] [PubMed]
- Szymanska, B.; Lukaszewski, Z.; Hermanowicz-Szamatowicz, K.; Gorodkiewicz, E. An immunosemsor for the determination of carcinoembryonic antygen by Surface Plasmon Resonance imaging. Anal. Biochem. 2020, 609, 113964. [Google Scholar] [CrossRef] [PubMed]
- Szymanska, B.; Lukaszewski, Z.; Oldak, L.; Zelazowska-Rutkowska, B.; Hermanowicz-Szamatowicz, K.; Gorodkiewicz, E. Two Biosensors for the Determination of Interleukin-6 in Blood Plasma by Array SPRi. Biosensors 2022, 12, 412. [Google Scholar] [CrossRef] [PubMed]
- Gorodkiewicz, E.; Sankiewicz, A.; Laudanski, P. Surface Plasmon Resonance Imaging biosensors for aromatase based on a potent inhibitor and a specific antibody: Sensor development and application for biological material. Cent. Eur. J. Chem. 2014, 12, 557–567. [Google Scholar] [CrossRef]
- Perez, B.H.; Gipson, I.K. Focus on molecules: Human mucin MUC16. Exp. Eye Res. 2008, 87, 400–401. [Google Scholar] [CrossRef] [Green Version]
- Bouanene, H.; Miled, A. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16. Dis. Markers 2010, 28, 385–394. [Google Scholar] [CrossRef]
- Huy, N.V.Q.; Khoa, V.V.; Tam, L.M.; Vinh, T.Q.; Tung, N.S.; Thanh, C.N.; Chuang, L. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecol. Oncol. Rep. 2018, 25, 110–114. [Google Scholar] [CrossRef]
- Li, J.; Wang, X.; Qu, W.; Wang, J.; Jiang, S.-W. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. Clin. Chim. Acta 2019, 488, 215–220. [Google Scholar] [CrossRef]
- Chen, F.; Shen, J.; Cai, P.; Huang, Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: Diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag. Res. 2018, 10, 1313–1318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bingle, L.; Singleton, V.; Bingle, C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21, 2768–2773. [Google Scholar] [CrossRef] [PubMed]
- Granato, T.; Porpora, M.G.; Longo, F.; Angeloni, A.; Manganaro, L.; Anastasi, E. HE4 in the differential diagnosis of ovarian masses. Clin. Chim. Acta 2015, 446, 147–155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anastasi, E.; Marchei, G.G.; Viggiani, V.; Gennarini, G.; Frati, L.; Reale, M.G. HE4: A new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010, 31, 113–119. [Google Scholar] [CrossRef] [PubMed]
- Gasiorowska, E.; Kluz, T.; Lipski, D.; Warchoł, W.; Tykarski, A.; Nowak-Markwitz, E. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors. Dis. Markers 2019, 2019, 3890906. [Google Scholar] [CrossRef] [Green Version]
- Ferraro, S.; Borille, S.; Carnevale, A.; Frusciante, E.; Bassani, N.; Panteghini, M. Verification of the harmonization of human epididymis protein 4 assays. Clin. Chem. Lab. Med. 2016, 54, 1635–1643. [Google Scholar] [CrossRef]
- Ferraro, S.; Panteghini, M. Making new biomarkers a reality: The case of serum human epididymis protein 4. Clin. Chem. Lab. Med. 2018, 57, 1284–1294. [Google Scholar] [CrossRef] [Green Version]
- Cho, H.-I.; Kim, H.J.; Oh, S.-T.; Kim, T.-G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003, 22, 224–236. [Google Scholar] [CrossRef]
- Thomas, P.; Toth, C.A.; Saini, K.S.; Jessup, J.M.; Steele, G., Jr. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim. Biophys. Acta 1990, 1032, 177–189. [Google Scholar] [CrossRef]
- Duffy, M.J. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin. Chem. 2001, 47, 624–630. [Google Scholar] [CrossRef] [Green Version]
- Thompson, J.A.; Grunert, F.; Zimmermann, W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J. Clin. Lab. Anal. 1991, 5, 344–366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamao, T.; Kai, S.; Kazami, A.; Koizumi, K.; Handa, T.; Takemoto, N.; Maruyama, M. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn. J. Clin. OncoI. 1999, 29, 550–555. [Google Scholar] [CrossRef] [PubMed]
- Aggarwal, C.; Meropol, N.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.A.; Mitchell, E. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann. Oncol. 2013, 24, 420–428. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.-C.; Yang, S.-H.; Lin, J.-K.; Lin, T.-C.; Chen, W.-S.; Jiang, J.-K.; Wang, H.-S.; Chang, S.-C. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J. Surg. Res. 2005, 124, 169–174. [Google Scholar] [CrossRef]
- Canizares, F.; Sola, J.; Perez, M.; Tpvar, I.; De Las Heras, M.; Salinas, J.; Panafiel, R.; Martinez, P. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: A multivariate analysis. Tumour Biol. 2001, 22, 273–281. [Google Scholar] [CrossRef]
- Distler, M.; Pilarsky, E.; Kersting, S.; Grutzmann, R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas—A retrospective tumor marker prognostic study. Int. J. Surg. 2013, 11, 1067–1072. [Google Scholar] [CrossRef] [Green Version]
- Ozkan, H.; Kaya, M.; Cengiz, A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenter 2003, 50, 1669–1674. [Google Scholar]
- Xie, Y.; Zhi, X.; Su, H.; Chen, D.; Cui, D. A novel electrochemical microfluidic chip combined with multiple biomarkers for early diagnosis of gastric cancer. Nanoscale Res. Lett. 2015, 10, 477. [Google Scholar] [CrossRef] [Green Version]
- Gao, Y.; Wang, J.; Zhou, Y.; Sheng, S.; Qian, S.Y.; Huo, X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci. Rep. 2018, 8, 2732. [Google Scholar] [CrossRef] [Green Version]
- Trovato, M.; Sciacchitano, S.; Facciolà, A.; Valenti, A.; Visalli, G.; di Pietro, A. Interleukin-6 signalling as a valuable cornerstone for molecular medicine (review). Int. J. Mol. Med. 2021, 47, 107. [Google Scholar] [CrossRef]
- Brabek, J.; Jakubek, M.; Vellieux, F.; Novotný, J.; Kolá, M.; Lacina, J.; Szabo, P.; Strnadová, K.; Rösel, D.; Dvoránková, B.; et al. Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19. Int. J. Mol. Sci. 2020, 21, 7937. [Google Scholar] [CrossRef] [PubMed]
- Amer, H.; Kartikasari, A.E.R.; Plebanski, M. Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis. J. Pers. Med. 2021, 11, 1335. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Li, J.; Liu, W.; Zhang, X.; Xue, L. The diagnostic value of interleukin 6 as a biomarker for gastric cancer: A meta-analysis and systematic review. Medicine 2021, 100, e27945. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Ye, Y.; Zhang, H.; Szmitkowski, M.; Mäkinen, M.J.; Li, P. Diagnostic and prognostic value of serum interleukin-6 in colorectal cancer. Medicine 2016, 95, 2502. [Google Scholar] [CrossRef] [PubMed]
- Tong, Q.; Wang, X.L.; Li, S.B.; Yang, G.L.; Jin, S.; Gao, Z.Y.; Liu, X.B. Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: A preliminary study based on the screening of serum markers using protein chips. OncoTargets Ther. 2018, 11, 5777–5787. [Google Scholar] [CrossRef] [Green Version]
- Kampan, N.C.; Madondo, M.T.; Reynolds, J.; Hallo, J.; McNally, O.M.; Jobling, T.W.; Stephens, A.N.; Quinn, M.A.; Plebanski, M. Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. Sci. Rep. 2020, 10, 221. [Google Scholar] [CrossRef] [Green Version]
- Montero, A.; Pascual, C.B.; Anaut, M.B.; López-Andrés, N.; Antona, G.; Martín-Calvo, N. Diagnostic performance of serum interleukin-6 in pediatric acute appendicitis: A systematic review. World J. Pediatr. 2022, 18, 91–99. [Google Scholar] [CrossRef]
- Hong, Y.; Li, H.; Yuan, Y.C.; Chen, S. Sequence-function correlation of aromatase and its interaction with reductase. J. Steroid Biochem. Mol. Biol. 2010, 118, 203–206. [Google Scholar] [CrossRef] [Green Version]
- Carreau, S.; Lambard, S.; Delaland, C.; Denis-Galeraud, I.; Bilinska, B.; Bourguiba, S. Aromatase expression and role of estrogens in male gonad: A review. Reprod. Biol. Endocrinol. 2003, 1, 352003. [Google Scholar] [CrossRef]
- Miedlich, S.U.; Karamooz, N.; Hammes, S.R. Aromatase deficiency in a male patient-case report and review of the literature. Bone 2016, 93, 181–186. [Google Scholar] [CrossRef]
- Manna, P.R.; Molehin, D.; Ahmed, A.U. Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies. Progr. Mol. Biol. Translat. Sci. 2016, 144, 487–537. [Google Scholar] [CrossRef]
- Guszcz, T.; Szymańska, B.; Kozlowski, R.; Lukaszewski, Z.; Laskowski, P.; Gorodkiewicz, E. Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis. Oncol. Lett. 2020, 19, 562–568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ermini, M.L.; Song, X.C.; Springer, T.; Homola, J. Peptide Functionalization of Gold Nanoparticles for the Detection of Carcinoembryonic Antigen in Blood Plasma via SPR-Based Biosensor. Front. Chem. 2019, 7, 40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, R.; Feng, F.; Chen, Z.-Z.; Bai, Y.-F.; Guo, F.-F.; Wu, F.Y.; Zhou, G. Sensitive detection of carcinoembryonic antigen using surface plasmon resonance biosensor with gold nanoparticles signal amplification. Talanta 2015, 140, 143–149. [Google Scholar] [CrossRef]
- Makaraviciute, A.; Ramanavicius, A.; Ramanaviciene, A. Development of a reusable protein G based SPR immunosensor for direct human growth hormone detection in real samples. Anal. Methods 2015, 7, 9875. [Google Scholar] [CrossRef]
- Kausaite-Minkstimiene, A.; Ramanavicius, A.; Ruksnaite, J.; Ramanaviciene, A. A surface plasmon resonance immunosensor for human growth hormone based on fragmented antibodies. Anal. Methods 2013, 5, 4757. [Google Scholar] [CrossRef]
- Moore, R.G.; McMeekin, D.S.; Brown, A.K.; Di Silvestro, P.; Miller, M.C.; Allard, W.J.; Gajewski, W.; Kurman, R.; Bast, R.C.; Skates, S.J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112, 40–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, C.; Zhang, N.; Zhong, A.; Xiao, K.; Lu, R.; Guo, L. A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than risk of ovarian malignancy algorithm (ROMA) in ovarian carcinoma. Clin. Chim. Acta 2022, 524, 43–50. [Google Scholar] [CrossRef]
Biomarker | Calibration Curve | Range/Units | R2 |
---|---|---|---|
CA125 | Y = 41.13X + 146 | 2.2–150/µg mL−1 | 0.995 |
HE4 | Y = 557.3X + 227 | 0.088–5.28/ng mL−1 | 0.991 |
CEA | Y = 151.5X + 85 | 0.40–20/ng mL−1 | 0.993 |
IL-6 | Y = 126X + 7.4 | 3–20/pg mL−1 | 0.992 |
Aromatase | Y = 1408X + 145 | 0.3–5/ng mL−1 | 0.994 |
Biomarker | RSD [%] | Average [%] | Range [%] |
---|---|---|---|
CA125 | 0.73; 3.0; 5.8; 3.5; 5.5; 1.6; 3.3; 3.8 | 3.4 | 0.73–5.8 |
HE4 | 2.5; 11; 1.0; 0.86; 1.1.; 0.58; 1.3; 10 | 3.5 | 0.58–11 |
CEA | 1.1; 1.6; 4.8; 2.7; 5.1; 7.6; 12; 5.4 | 5.0 | 1.1–12 |
IL-6 | 1.8; 5.2; 2.3; 3.8; 3.4; 3.9; 9.0; 11 | 5.0 | 1.8–11 |
Aromatase | 1.4; 2.9; 1.6; 2.3; 13; 1.6; 15; 23 | 7.6 | 1.4–23 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szymanska, B.; Lukaszewski, Z.; Hermanowicz-Szamatowicz, K.; Gorodkiewicz, E. A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases. Biosensors 2023, 13, 279. https://doi.org/10.3390/bios13020279
Szymanska B, Lukaszewski Z, Hermanowicz-Szamatowicz K, Gorodkiewicz E. A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases. Biosensors. 2023; 13(2):279. https://doi.org/10.3390/bios13020279
Chicago/Turabian StyleSzymanska, Beata, Zenon Lukaszewski, Kinga Hermanowicz-Szamatowicz, and Ewa Gorodkiewicz. 2023. "A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases" Biosensors 13, no. 2: 279. https://doi.org/10.3390/bios13020279